סקייריזי 180 מ"ג - Skyrizi 180 mg
×××ר××
×צפ××× ×××××¢ ××ר×× ×ר×פ××× ×ש ××××× ×¡ ××ש××× ×. ×× ××× × ×¨×©×× ××× ×¡ ××רש×× ×ר×פ××× ××× ×©× ×קצ××¢×ת רפ×××××.
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L04AC Interleukin inhibitors | ||||||||||||||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||||||||||||||
| צ×רת ××ª× | תת-×¢××¨× - S.C | ||||||||||||||||||
| צ×רת ××× ×× | ת×××¡× ×××רק×, SOLUTION FOR INJECTION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||||||||||||||
| ×ת×××× | Skyrizi is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological therapy. | ||||||||||||||||||
| |||||||||||||||||||
| ×ת××ת ××× ×× | Posology and method of administration | ||||||||||||||||||
| ×ת××××ת × ×× | Contraindications | ||||||||||||||||||
| ת×פע×ת ××××× | Undesirable effects | ||||||||||||||||||
| ת××××ת ××× ×ª×¨×פת××ת | Interaction with other medicinal products and other forms of interaction | ||||||||||||||||||
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation | ||||||||||||||||||
| פר×ק×××× ×××§× | Pharmacodynamic Properties | ||||||||||||||||||
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties | ||||||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | ||||||||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| סק××ר××× 180 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | ABBVIE DEUTSCHLAND GMBH & CO. KG, GERMANY |
| ×©× ××¢× ×ר×ש×× | ABBVIE BIOPHARMACEUTICALS LTD, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 8/2024. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 22/08/2025 |
השינוי האחרון נעשה בֹ־22 באוגוסט 2025 ב־06:46